A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

NCT05132582 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

654

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2 Positive Breast Cancer

Interventions

DRUG: Tucatinib
DRUG: Trastuzumab
DRUG: Pertuzumab
DRUG: Combination product: Trastuzumab + Pertuzumab
DRUG: Placebo

Sponsor

Seagen, a wholly owned subsidiary of Pfizer